Pfizer recently announced positive results from the BASIS study, the global phase 3 trial evaluating Hympavzi in young adults ...

On June 26, Pfizer announced positive topline results from its Phase 3 BASIS study evaluating HYMPAVZI (marstacimab) for ...

NEW YORK, NY, USA I June 26, 2025 I Pfizer Inc. (NYSE: PFE)today announced positive topline results from the Phase 3 BASIS study (NCT03938792) evaluating ...

Pfizer PFE announced that the phase III BASIS study evaluating its anti-TFPI inhibitor Hympavzi (marstacimab) for treating patients with hemophilia A or B with inhibitors met its primary endpoint as ...

Pfizer announces positive results from phase 3 BASIS study of Hympavzi in haemophilia A or B with inhibitors: New York Friday, June 27, 2025, 10:00 Hrs [IST] Pfizer Inc. announced ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% compared to on-demand treatment with bypassing agents in patients with ...

COVID-19 患者血浆组织因子途径抑制物（TFPI）水平升高，但其在凝血中的作用不明。研究人员利用 COVID-19 临床试验血样，测定 TFPI 和凝血酶生成等。结果发现 TFPI 延迟凝血酶生成和凝块形成，但与血栓等临床结局无关，为理解 COVID-19 凝血机制提供依据。

Tissue factor pathway inhibitor (TFPI) plays a vitally important role in the blood coagulation pathway. Recent studies indicated that TFPI induces apoptosis in vascular smooth-muscle cells (VSMCs) in ...

组织因子途径抑制剂（TFPI）：预测慢性肾病和糖尿病患者动脉粥样硬化血栓事件的新希望？ 【字体： 大 中 小 】 时间：2025年03月17日 来源：Journal of Thrombosis and Thrombolysis 2.3 ...

The following is a summary of “Effect of therapeutic plasma exchange on tissue factor and tissue factor pathway inhibitor in septic shock,” published in the October 2024 issue of Critical Care by ...

TFPI试剂盒；大鼠组织因子通道抑制因子(TFPI)ELISA试剂盒每次实验的标准曲线一般设7个不同浓度，加上空白孔，标准曲线一共需要 8个孔。